Skip to main content
Erschienen in: Cancer and Metastasis Reviews 1/2020

06.02.2020

Cardiovascular diseases in survivors of childhood cancer

verfasst von: Neha Bansal, Javier G. Blanco, Umesh C. Sharma, Saraswati Pokharel, Shannon Shisler, Steven E. Lipshultz

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Over the past few decades, the diagnosis and management of children with various malignancies have improved tremendously. As a result, there are an increasing number of children who are long-term cancer survivors. With improved survival, however, has come an increased risk of treatment-related cardiovascular complications that can appear decades after treatment. These problems are serious enough that all caregivers of childhood cancer survivors, including oncologists, cardiologists, and other health care personnel, must pay close attention to the short- and long-term effects of chemotherapy and radiotherapy on these children. This review discusses the effects of treatment-related cardiovascular complications from anthracyclines and radiotherapy and the methods for preventing, screening, and treating these complications.
Literatur
1.
Zurück zum Zitat Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians, 66(4), 271–289. Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: a Cancer Journal for Clinicians, 66(4), 271–289.
2.
Zurück zum Zitat Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007). Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy, 8(8), 1039–1058.CrossRefPubMed Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007). Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy, 8(8), 1039–1058.CrossRefPubMed
3.
Zurück zum Zitat Siegel, R. L., Miller, K. D., Jemal, A., & Cancer statistics. (2015). CA: a Cancer Journal for Clinicians, 65(1), 5–29. Siegel, R. L., Miller, K. D., Jemal, A., & Cancer statistics. (2015). CA: a Cancer Journal for Clinicians, 65(1), 5–29.
4.
Zurück zum Zitat Scully, R. E., & Lipshultz, S. E. (2007). Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology, 7(2), 122–128.CrossRefPubMed Scully, R. E., & Lipshultz, S. E. (2007). Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology, 7(2), 122–128.CrossRefPubMed
5.
Zurück zum Zitat Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., et al. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ., 339, b4606.CrossRefPubMedPubMedCentral Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., et al. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ., 339, b4606.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Mertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008). Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 100(19), 1368–1379.CrossRefPubMedPubMedCentral Mertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008). Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 100(19), 1368–1379.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., Robison, L. L., & Childhood Cancer Survivor Study. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355(15), 1572–1582.CrossRefPubMed Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., Robison, L. L., & Childhood Cancer Survivor Study. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355(15), 1572–1582.CrossRefPubMed
8.
Zurück zum Zitat Lipshultz, S. E., & Adams, M. J. (2010). Cardiotoxicity after childhood cancer: beginning with the end in mind. Journal of Clinical Oncology, 28(8), 1276–1281.CrossRefPubMed Lipshultz, S. E., & Adams, M. J. (2010). Cardiotoxicity after childhood cancer: beginning with the end in mind. Journal of Clinical Oncology, 28(8), 1276–1281.CrossRefPubMed
9.
Zurück zum Zitat Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., Winter, D., Bourhis, J., Lefkopoulos, D., Diallo, I., & de Vathaire, F. (2010). Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. Journal of Clinical Oncology, 28(8), 1308–1315.CrossRefPubMed Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., Winter, D., Bourhis, J., Lefkopoulos, D., Diallo, I., & de Vathaire, F. (2010). Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. Journal of Clinical Oncology, 28(8), 1308–1315.CrossRefPubMed
10.
Zurück zum Zitat Levitt, G., Anazodo, A., Burch, M., & Bunch, K. (2009). Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? European Journal of Cancer, 45(17), 3027–3034.CrossRefPubMed Levitt, G., Anazodo, A., Burch, M., & Bunch, K. (2009). Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? European Journal of Cancer, 45(17), 3027–3034.CrossRefPubMed
11.
Zurück zum Zitat Valcovici, M., Andrica, F., Serban, C., & Dragan, S. (2016). Cardiotoxicity of anthracycline therapy: current perspectives. Archives of Medical Science, 12(2), 428–435.CrossRefPubMedPubMedCentral Valcovici, M., Andrica, F., Serban, C., & Dragan, S. (2016). Cardiotoxicity of anthracycline therapy: current perspectives. Archives of Medical Science, 12(2), 428–435.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Nysom, K., Holm, K., Lipsitz, S. R., Mone, S. M., Colan, S. D., Orav, E. J., Sallan, S. E., Olsen, J. H., Hertz, H., Jacobsen, J. R., & Lipshultz, S. E. (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16(2), 545–550.CrossRefPubMed Nysom, K., Holm, K., Lipsitz, S. R., Mone, S. M., Colan, S. D., Orav, E. J., Sallan, S. E., Olsen, J. H., Hertz, H., Jacobsen, J. R., & Lipshultz, S. E. (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16(2), 545–550.CrossRefPubMed
13.
Zurück zum Zitat Chu E SA: cancer chemotherapy, 9th ed edn. New York: Lange Medical Books/McGraw-Hill 2004. Chu E SA: cancer chemotherapy, 9th ed edn. New York: Lange Medical Books/McGraw-Hill 2004.
14.
Zurück zum Zitat Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008). Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart., 94(4), 525–533.CrossRefPubMed Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008). Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart., 94(4), 525–533.CrossRefPubMed
15.
Zurück zum Zitat Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., & Gersl, V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 61(1), 154–171.CrossRefPubMed Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., & Gersl, V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 61(1), 154–171.CrossRefPubMed
16.
Zurück zum Zitat De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2010). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation., 121(2), 276–292.CrossRefPubMed De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2010). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation., 121(2), 276–292.CrossRefPubMed
17.
Zurück zum Zitat Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234–235(1–2), 119–124.CrossRefPubMed Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234–235(1–2), 119–124.CrossRefPubMed
18.
Zurück zum Zitat Jurcut, R., Wildiers, H., Ganame, J., D'Hooge, J., Paridaens, R., & Voigt, J. U. (2008). Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Supportive Care in Cancer, 16(5), 437–445.CrossRefPubMed Jurcut, R., Wildiers, H., Ganame, J., D'Hooge, J., Paridaens, R., & Voigt, J. U. (2008). Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Supportive Care in Cancer, 16(5), 437–445.CrossRefPubMed
19.
Zurück zum Zitat Rusconi, P., Gomez-Marin, O., Rossique-Gonzalez, M., Redha, E., Marin, J. R., Lon-Young, M., et al. (2004). Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation, 23(7), 832–838.CrossRefPubMed Rusconi, P., Gomez-Marin, O., Rossique-Gonzalez, M., Redha, E., Marin, J. R., Lon-Young, M., et al. (2004). Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation, 23(7), 832–838.CrossRefPubMed
20.
Zurück zum Zitat Lowis, S., Lewis, I., Elsworth, A., Weston, C., Doz, F., Vassal, G., Bellott, R., Robert, J., Pein, F., Ablett, S., Pinkerton, R., Frappaz, D., United Kingdom Children’s Cancer Study Group (UKCCSG) New Agents, & Société Française d’Oncologie Pédiatrique (SFOP) Pharmacology Group. (2006). A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British Journal of Cancer, 95(5), 571–580.CrossRefPubMedPubMedCentral Lowis, S., Lewis, I., Elsworth, A., Weston, C., Doz, F., Vassal, G., Bellott, R., Robert, J., Pein, F., Ablett, S., Pinkerton, R., Frappaz, D., United Kingdom Children’s Cancer Study Group (UKCCSG) New Agents, & Société Française d’Oncologie Pédiatrique (SFOP) Pharmacology Group. (2006). A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British Journal of Cancer, 95(5), 571–580.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., & Walker, U. A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. The Journal of Pathology, 207(4), 436–444.CrossRefPubMed Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., & Walker, U. A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. The Journal of Pathology, 207(4), 436–444.CrossRefPubMed
22.
Zurück zum Zitat Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Journal of the National Cancer Institute, 100(15), 1058–1067.CrossRefPubMed Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Journal of the National Cancer Institute, 100(15), 1058–1067.CrossRefPubMed
23.
Zurück zum Zitat Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine, 18(11), 1639–1642.CrossRefPubMed Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine, 18(11), 1639–1642.CrossRefPubMed
24.
Zurück zum Zitat Khiati, S., Dalla Rosa, I., Sourbier, C., Ma, X., Rao, V. A., Neckers, L. M., Zhang, H., & Pommier, Y. (2014). Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clinical Cancer Research, 20(18), 4873–4881.CrossRefPubMedPubMedCentral Khiati, S., Dalla Rosa, I., Sourbier, C., Ma, X., Rao, V. A., Neckers, L. M., Zhang, H., & Pommier, Y. (2014). Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clinical Cancer Research, 20(18), 4873–4881.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine, 324(12), 808–815.CrossRefPubMed Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine, 324(12), 808–815.CrossRefPubMed
26.
Zurück zum Zitat Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332(26), 1738–1743.CrossRefPubMed Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332(26), 1738–1743.CrossRefPubMed
27.
Zurück zum Zitat Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997). Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Journal of Clinical Oncology, 15(4), 1544–1552.CrossRefPubMed Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997). Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Journal of Clinical Oncology, 15(4), 1544–1552.CrossRefPubMed
28.
Zurück zum Zitat Lipshultz, S. E., Karnik, R., Sambatakos, P., Franco, V. I., Ross, S. W., & Miller, T. L. (2014). Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology, 29(1), 103–112.CrossRefPubMed Lipshultz, S. E., Karnik, R., Sambatakos, P., Franco, V. I., Ross, S. W., & Miller, T. L. (2014). Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology, 29(1), 103–112.CrossRefPubMed
29.
Zurück zum Zitat Rinehart, J. J., Lewis, R. P., & Balcerzak, S. P. (1974). Adriamycin cardiotoxicity in man. Annals of Internal Medicine, 81(4), 475–478.CrossRefPubMed Rinehart, J. J., Lewis, R. P., & Balcerzak, S. P. (1974). Adriamycin cardiotoxicity in man. Annals of Internal Medicine, 81(4), 475–478.CrossRefPubMed
30.
Zurück zum Zitat Grenier, M. A., & Lipshultz, S. E. (1998). Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology, 25(4 Suppl 10), 72–85.PubMed Grenier, M. A., & Lipshultz, S. E. (1998). Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology, 25(4 Suppl 10), 72–85.PubMed
31.
Zurück zum Zitat Bryant, J., Picot, J., Levitt, G., Sullivan, I., Baxter, L., & Clegg, A. (2007). Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess, 11(27):iii, ix-x), 1–84.CrossRef Bryant, J., Picot, J., Levitt, G., Sullivan, I., Baxter, L., & Clegg, A. (2007). Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess, 11(27):iii, ix-x), 1–84.CrossRef
32.
Zurück zum Zitat Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voute, P. A. (2002). Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology, 13(6), 819–829.CrossRefPubMed Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voute, P. A. (2002). Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology, 13(6), 819–829.CrossRefPubMed
33.
Zurück zum Zitat Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., et al. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337.CrossRefPubMedPubMedCentral Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., et al. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Wojnowski, L., Kulle, B., Schirmer, M., Schluter, G., Schmidt, A., & Rosenberger, A. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation., 112. Wojnowski, L., Kulle, B., Schirmer, M., Schluter, G., Schmidt, A., & Rosenberger, A. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation., 112.
35.
Zurück zum Zitat Linschoten, M., Teske, A. J., Cramer, M. J., van der Wall, E., & Asselbergs, F. W. (2018). Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med., 11(1), e001753.CrossRefPubMed Linschoten, M., Teske, A. J., Cramer, M. J., van der Wall, E., & Asselbergs, F. W. (2018). Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med., 11(1), e001753.CrossRefPubMed
37.
Zurück zum Zitat Aminkeng, F., Ross, C. J., Rassekh, S. R., Hwang, S., Rieder, M. J., Bhavsar, A. P., Smith, A., Sanatani, S., Gelmon, K. A., Bernstein, D., Hayden, M. R., Amstutz, U., Carleton, B. C., & CPNDS Clinical Practice Recommendations Group. (2016). Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. British Journal of Clinical Pharmacology, 82(3), 683–695.CrossRefPubMedPubMedCentral Aminkeng, F., Ross, C. J., Rassekh, S. R., Hwang, S., Rieder, M. J., Bhavsar, A. P., Smith, A., Sanatani, S., Gelmon, K. A., Bernstein, D., Hayden, M. R., Amstutz, U., Carleton, B. C., & CPNDS Clinical Practice Recommendations Group. (2016). Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. British Journal of Clinical Pharmacology, 82(3), 683–695.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Magdy, T., Burmeister, B. T., & Burridge, P. W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacology & Therapeutics, 168, 113–125.CrossRef Magdy, T., Burmeister, B. T., & Burridge, P. W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacology & Therapeutics, 168, 113–125.CrossRef
39.
Zurück zum Zitat Leong, S. L., Chaiyakunapruk, N., & Lee, S. W. (2017). Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis., 7(1), 39. Leong, S. L., Chaiyakunapruk, N., & Lee, S. W. (2017). Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis., 7(1), 39.
40.
Zurück zum Zitat Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I., Davies, S. M., Relling, M. V., Robison, L. L., Sklar, C. A., Stovall, M., & Bhatia, S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer., 112(12), 2789–2795.CrossRefPubMed Blanco, J. G., Leisenring, W. M., Gonzalez-Covarrubias, V. M., Kawashima, T. I., Davies, S. M., Relling, M. V., Robison, L. L., Sklar, C. A., Stovall, M., & Bhatia, S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer., 112(12), 2789–2795.CrossRefPubMed
41.
Zurück zum Zitat Blanco, J. G., Sun, C. L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., Neglia, J. P., Oeffinger, K. C., Ritchey, A. K., Villaluna, D., Relling, M. V., & Bhatia, S. (2012). Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children’s Oncology Group. Journal of Clinical Oncology, 30(13), 1415–1421.CrossRefPubMed Blanco, J. G., Sun, C. L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., Neglia, J. P., Oeffinger, K. C., Ritchey, A. K., Villaluna, D., Relling, M. V., & Bhatia, S. (2012). Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children’s Oncology Group. Journal of Clinical Oncology, 30(13), 1415–1421.CrossRefPubMed
42.
Zurück zum Zitat Salvatorelli, E., Menna, P., Chello, M., Covino, E., & Minotti, G. (2018). Low-dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites. The Journal of Pharmacology and Experimental Therapeutics, 364(2), 323–331.CrossRefPubMed Salvatorelli, E., Menna, P., Chello, M., Covino, E., & Minotti, G. (2018). Low-dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites. The Journal of Pharmacology and Experimental Therapeutics, 364(2), 323–331.CrossRefPubMed
43.
Zurück zum Zitat Wang, X., Sun, C. L., Quinones-Lombrana, A., Singh, P., Landier, W., Hageman, L., et al. (2016). CELF4 variant and anthracycline-related cardiomyopathy: a Children’s Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology, 34(8), 863–870.CrossRefPubMedPubMedCentral Wang, X., Sun, C. L., Quinones-Lombrana, A., Singh, P., Landier, W., Hageman, L., et al. (2016). CELF4 variant and anthracycline-related cardiomyopathy: a Children’s Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology, 34(8), 863–870.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B. (2013). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer., 119(19), 3555–3562.CrossRefPubMed Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B. (2013). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer., 119(19), 3555–3562.CrossRefPubMed
45.
Zurück zum Zitat Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of Clinical Oncology, 33(5), 394–402.CrossRefPubMed Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of Clinical Oncology, 33(5), 394–402.CrossRefPubMed
46.
Zurück zum Zitat Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2009). New developments in anthracycline-induced cardiotoxicity. Current Medicinal Chemistry, 16(13), 1656–1672.CrossRefPubMed Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2009). New developments in anthracycline-induced cardiotoxicity. Current Medicinal Chemistry, 16(13), 1656–1672.CrossRefPubMed
47.
Zurück zum Zitat Brown, S. A., Sandhu, N., & Herrmann, J. (2015). Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature Reviews. Clinical Oncology, 12(12), 718–731.CrossRefPubMed Brown, S. A., Sandhu, N., & Herrmann, J. (2015). Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature Reviews. Clinical Oncology, 12(12), 718–731.CrossRefPubMed
48.
Zurück zum Zitat Lenihan, D. J., Oliva, S., Chow, E. J., & Cardinale, D. (2013). Cardiac toxicity in cancer survivors. Cancer., 119, 2131–2142.CrossRefPubMed Lenihan, D. J., Oliva, S., Chow, E. J., & Cardinale, D. (2013). Cardiac toxicity in cancer survivors. Cancer., 119, 2131–2142.CrossRefPubMed
49.
Zurück zum Zitat Lipshultz, S. E., Cochran, T. R., Franco, V. I., & Miller, T. L. (2013). Treatment-related cardiotoxicity in survivors of childhood cancer. Nature Reviews. Clinical Oncology, 10(12), 697–710.CrossRefPubMed Lipshultz, S. E., Cochran, T. R., Franco, V. I., & Miller, T. L. (2013). Treatment-related cardiotoxicity in survivors of childhood cancer. Nature Reviews. Clinical Oncology, 10(12), 697–710.CrossRefPubMed
50.
Zurück zum Zitat Wang, X., Chen, Y., Hageman, L., Singh, P., Landier, W., Blanco, J. G., et al. (2019). Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report., 37(15_suppl), 10015–10015. Wang, X., Chen, Y., Hageman, L., Singh, P., Landier, W., Blanco, J. G., et al. (2019). Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report., 37(15_suppl), 10015–10015.
51.
Zurück zum Zitat Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., & Lipshultz, S. E. (1998). Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology, 27(1), 53–68.CrossRefPubMed Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., & Lipshultz, S. E. (1998). Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology, 27(1), 53–68.CrossRefPubMed
52.
Zurück zum Zitat Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., & Lipshultz, S. E. (2005). Cardiotoxicity of cancer chemotherapy: implications for children. Paediatric Drugs, 7(3), 187–202.CrossRefPubMed Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., & Lipshultz, S. E. (2005). Cardiotoxicity of cancer chemotherapy: implications for children. Paediatric Drugs, 7(3), 187–202.CrossRefPubMed
53.
Zurück zum Zitat Adams, M. J., & Lipshultz, S. E. (2005). Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood & Cancer, 44(7), 600–606.CrossRef Adams, M. J., & Lipshultz, S. E. (2005). Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood & Cancer, 44(7), 600–606.CrossRef
54.
Zurück zum Zitat Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011). Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology, 32(3), 342–353.CrossRefPubMed Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011). Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology, 32(3), 342–353.CrossRefPubMed
55.
Zurück zum Zitat Bristow, M. R., Mason, J. W., Billingham, M. E., & Daniels, J. R. (1978). Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Annals of Internal Medicine, 88(2), 168–175.CrossRefPubMed Bristow, M. R., Mason, J. W., Billingham, M. E., & Daniels, J. R. (1978). Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Annals of Internal Medicine, 88(2), 168–175.CrossRefPubMed
56.
Zurück zum Zitat Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23(12), 2629–2636.CrossRefPubMed Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23(12), 2629–2636.CrossRefPubMed
57.
Zurück zum Zitat Lipshultz, S. E., Scully, R. E., Stevenson, K. E., Franco, V. I., Neuberg, D. S., Colan, S. D., et al. (2014). Hearts too small for body size after doxorubicin for childhood leukemia: Grinch syndrome. J Clin Oncol, 32, –10021 (abstr.). Lipshultz, S. E., Scully, R. E., Stevenson, K. E., Franco, V. I., Neuberg, D. S., Colan, S. D., et al. (2014). Hearts too small for body size after doxorubicin for childhood leukemia: Grinch syndrome. J Clin Oncol, 32, –10021 (abstr.).
58.
Zurück zum Zitat Wouters, K. A., Kremer, L. C., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. British Journal of Haematology, 131(5), 561–578.CrossRefPubMed Wouters, K. A., Kremer, L. C., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. British Journal of Haematology, 131(5), 561–578.CrossRefPubMed
59.
Zurück zum Zitat Lipshultz, S. E. (1996). Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Journal of Clinical Oncology, 14(2), 328–331.CrossRefPubMed Lipshultz, S. E. (1996). Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Journal of Clinical Oncology, 14(2), 328–331.CrossRefPubMed
60.
Zurück zum Zitat Hasinoff, B. B., & Herman, E. H. (2007). Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology, 7(2), 140–144.CrossRefPubMed Hasinoff, B. B., & Herman, E. H. (2007). Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology, 7(2), 140–144.CrossRefPubMed
61.
Zurück zum Zitat Hutchins, K. K., Siddeek, H., Franco, V. I., & Lipshultz, S. E. (2017). Prevention of cardiotoxicity among survivors of childhood cancer. British Journal of Clinical Pharmacology, 83(3), 455–465.CrossRefPubMed Hutchins, K. K., Siddeek, H., Franco, V. I., & Lipshultz, S. E. (2017). Prevention of cardiotoxicity among survivors of childhood cancer. British Journal of Clinical Pharmacology, 83(3), 455–465.CrossRefPubMed
62.
Zurück zum Zitat Vejpongsa, P., & Yeh, E. T. (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938–945.CrossRefPubMed Vejpongsa, P., & Yeh, E. T. (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938–945.CrossRefPubMed
63.
Zurück zum Zitat Chang, H. M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017). Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. Journal of the American College of Cardiology, 70(20), 2536–2551.CrossRefPubMedPubMedCentral Chang, H. M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017). Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. Journal of the American College of Cardiology, 70(20), 2536–2551.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation., 96(8), 2641–2648.CrossRefPubMed Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation., 96(8), 2641–2648.CrossRefPubMed
65.
Zurück zum Zitat Armenian, S. H., & Ehrhardt, M. J. (2019). Optimizing cardiovascular care in children with acute myeloid leukemia to improve cancer-related outcomes. Journal of Clinical Oncology, 37(1), 1–6.CrossRefPubMed Armenian, S. H., & Ehrhardt, M. J. (2019). Optimizing cardiovascular care in children with acute myeloid leukemia to improve cancer-related outcomes. Journal of Clinical Oncology, 37(1), 1–6.CrossRefPubMed
67.
Zurück zum Zitat Reichardt, P., Tabone, M. D., Mora, J., Morland, B., & Jones, R. L. (2018). Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology. Reichardt, P., Tabone, M. D., Mora, J., Morland, B., & Jones, R. L. (2018). Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology.
68.
Zurück zum Zitat Lipshultz, S. E. (2018). Letter by Lipshultz regarding article, “Anthracycline cardiotoxicity: worrisome enough to have you quaking?”. Circulation Research, 122(7), e62–e63.CrossRefPubMedPubMedCentral Lipshultz, S. E. (2018). Letter by Lipshultz regarding article, “Anthracycline cardiotoxicity: worrisome enough to have you quaking?”. Circulation Research, 122(7), e62–e63.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Bansal, N., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2017). Chemotherapy-induced cardiotoxicity in children. Expert Opinion on Drug Metabolism & Toxicology, 13(8), 817–832.CrossRef Bansal, N., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2017). Chemotherapy-induced cardiotoxicity in children. Expert Opinion on Drug Metabolism & Toxicology, 13(8), 817–832.CrossRef
70.
Zurück zum Zitat Lipshultz, S. E., & Herman, E. H. (2018). Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovascular Research, 114(2), 205–209.CrossRefPubMed Lipshultz, S. E., & Herman, E. H. (2018). Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovascular Research, 114(2), 205–209.CrossRefPubMed
71.
Zurück zum Zitat Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., et al. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology., 5(1), 18.CrossRefPubMedPubMedCentral Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., et al. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology., 5(1), 18.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Cardinale, D., Ciceri, F., Latini, R., Franzosi, M. G., Sandri, M. T., Civelli, M., Cucchi, G., Menatti, E., Mangiavacchi, M., Cavina, R., Barbieri, E., Gori, S., Colombo, A., Curigliano, G., Salvatici, M., Rizzo, A., Ghisoni, F., Bianchi, A., Falci, C., Aquilina, M., Rocca, A., Monopoli, A., Milandri, C., Rossetti, G., Bregni, M., Sicuro, M., Malossi, A., Nassiacos, D., Verusio, C., Giordano, M., Staszewsky, L., Barlera, S., Nicolis, E. B., Magnoli, M., Masson, S., Cipolla, C. M., & ICOS-ONE Study Investigators. (2018). Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. European Journal of Cancer, 94, 126–137.CrossRefPubMed Cardinale, D., Ciceri, F., Latini, R., Franzosi, M. G., Sandri, M. T., Civelli, M., Cucchi, G., Menatti, E., Mangiavacchi, M., Cavina, R., Barbieri, E., Gori, S., Colombo, A., Curigliano, G., Salvatici, M., Rizzo, A., Ghisoni, F., Bianchi, A., Falci, C., Aquilina, M., Rocca, A., Monopoli, A., Milandri, C., Rossetti, G., Bregni, M., Sicuro, M., Malossi, A., Nassiacos, D., Verusio, C., Giordano, M., Staszewsky, L., Barlera, S., Nicolis, E. B., Magnoli, M., Masson, S., Cipolla, C. M., & ICOS-ONE Study Investigators. (2018). Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. European Journal of Cancer, 94, 126–137.CrossRefPubMed
73.
Zurück zum Zitat Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of Clinical Oncology, 25(25), 3991–4008.CrossRefPubMed Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of Clinical Oncology, 25(25), 3991–4008.CrossRefPubMed
74.
Zurück zum Zitat Burnett Jr., H. W., Steinberg, I., & Dotter, C. T. (1952). Seven-year survival after radiation therapy in a patient with inoperable cancer of the lung. The New England Journal of Medicine, 247(22), 850–851.CrossRefPubMed Burnett Jr., H. W., Steinberg, I., & Dotter, C. T. (1952). Seven-year survival after radiation therapy in a patient with inoperable cancer of the lung. The New England Journal of Medicine, 247(22), 850–851.CrossRefPubMed
75.
Zurück zum Zitat Wu, L., Pang, S., Yao, Q., Jian, C., Lin, P., Feng, F., Li, H., & Li, Y. (2017). Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. Scientific Reports, 7(1), 3471.CrossRefPubMedPubMedCentral Wu, L., Pang, S., Yao, Q., Jian, C., Lin, P., Feng, F., Li, H., & Li, Y. (2017). Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age. Scientific Reports, 7(1), 3471.CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Thames Jr., H. D., Withers, H. R., Peters, L. J., & Fletcher, G. H. (1982). Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. International Journal of Radiation Oncology, Biology, Physics, 8(2), 219–226.CrossRefPubMed Thames Jr., H. D., Withers, H. R., Peters, L. J., & Fletcher, G. H. (1982). Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. International Journal of Radiation Oncology, Biology, Physics, 8(2), 219–226.CrossRefPubMed
77.
Zurück zum Zitat Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., et al. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England Journal of Medicine, 368(11), 987–998.CrossRefPubMed Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., et al. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England Journal of Medicine, 368(11), 987–998.CrossRefPubMed
78.
Zurück zum Zitat Ming, X., Feng, Y., Yang, C., Wang, W., Wang, P., & Deng, J. (2016). Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update. Medicine (Baltimore), 95(41), e5051.CrossRef Ming, X., Feng, Y., Yang, C., Wang, W., Wang, P., & Deng, J. (2016). Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update. Medicine (Baltimore), 95(41), e5051.CrossRef
79.
Zurück zum Zitat Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., Tate, D. J., Horning, S. J., Hoppe, R. T., & Hancock, S. L. (2007). Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. Journal of Clinical Oncology, 25(1), 43–49.CrossRefPubMed Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., Tate, D. J., Horning, S. J., Hoppe, R. T., & Hancock, S. L. (2007). Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. Journal of Clinical Oncology, 25(1), 43–49.CrossRefPubMed
80.
Zurück zum Zitat Kole, T. P., Aghayere, O., Kwah, J., Yorke, E. D., & Goodman, K. A. (2012). Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1580–1586.CrossRefPubMed Kole, T. P., Aghayere, O., Kwah, J., Yorke, E. D., & Goodman, K. A. (2012). Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1580–1586.CrossRefPubMed
81.
Zurück zum Zitat Wu, W. C., Chan, C. L., Wong, Y. W., & Cuijpers, J. P. (2010). A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. The British Journal of Radiology, 83(987), 252–256.CrossRefPubMedPubMedCentral Wu, W. C., Chan, C. L., Wong, Y. W., & Cuijpers, J. P. (2010). A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. The British Journal of Radiology, 83(987), 252–256.CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Fajardo, L. F., Eltringham, J. R., & Steward, J. R. (1976). Combined cardiotoxicity of adriamycin and x-radiation. Laboratory Investigation, 34(1), 86–96.PubMed Fajardo, L. F., Eltringham, J. R., & Steward, J. R. (1976). Combined cardiotoxicity of adriamycin and x-radiation. Laboratory Investigation, 34(1), 86–96.PubMed
83.
Zurück zum Zitat Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., Pham, L., Chen, H. H., Burnett, J. C., Russell, S. J., & Redfield, M. M. (2017). Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. American Journal of Physiology. Heart and Circulatory Physiology, 313(2), H392–H407.CrossRefPubMedPubMedCentral Saiki, H., Moulay, G., Guenzel, A. J., Liu, W., Decklever, T. D., Classic, K. L., Pham, L., Chen, H. H., Burnett, J. C., Russell, S. J., & Redfield, M. M. (2017). Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. American Journal of Physiology. Heart and Circulatory Physiology, 313(2), H392–H407.CrossRefPubMedPubMedCentral
85.
Zurück zum Zitat Schultz-Hector, S., & Trott, K. R. (2007). Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? International Journal of Radiation Oncology, Biology, Physics, 67(1), 10–18.CrossRefPubMed Schultz-Hector, S., & Trott, K. R. (2007). Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? International Journal of Radiation Oncology, Biology, Physics, 67(1), 10–18.CrossRefPubMed
86.
Zurück zum Zitat Yarnold, J., & Brotons, M. C. (2010). Pathogenetic mechanisms in radiation fibrosis. Radiotherapy and Oncology, 97(1), 149–161.CrossRefPubMed Yarnold, J., & Brotons, M. C. (2010). Pathogenetic mechanisms in radiation fibrosis. Radiotherapy and Oncology, 97(1), 149–161.CrossRefPubMed
87.
Zurück zum Zitat Stewart, J. R., & Fajardo, L. F. (1984). Radiation-induced heart disease: an update. Progress in Cardiovascular Diseases, 27(3), 173–194.CrossRefPubMed Stewart, J. R., & Fajardo, L. F. (1984). Radiation-induced heart disease: an update. Progress in Cardiovascular Diseases, 27(3), 173–194.CrossRefPubMed
88.
Zurück zum Zitat Shapiro, C. L. (2018). Cancer survivorship. The New England Journal of Medicine, 379(25), 2438–2450.CrossRefPubMed Shapiro, C. L. (2018). Cancer survivorship. The New England Journal of Medicine, 379(25), 2438–2450.CrossRefPubMed
89.
Zurück zum Zitat Shapiro, C. L., & Recht, A. (2001). Side effects of adjuvant treatment of breast cancer. The New England Journal of Medicine, 344(26), 1997–2008.CrossRefPubMed Shapiro, C. L., & Recht, A. (2001). Side effects of adjuvant treatment of breast cancer. The New England Journal of Medicine, 344(26), 1997–2008.CrossRefPubMed
90.
Zurück zum Zitat Loffler, A. I., & Bourque, J. M. (2016). Coronary microvascular dysfunction, microvascular angina, and management. Current Cardiology Reports, 18(1), 1.CrossRefPubMedPubMedCentral Loffler, A. I., & Bourque, J. M. (2016). Coronary microvascular dysfunction, microvascular angina, and management. Current Cardiology Reports, 18(1), 1.CrossRefPubMedPubMedCentral
91.
Zurück zum Zitat Melikian, N., De Bruyne, B., Fearon, W. F., & MacCarthy, P. A. (2008). The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Progress in Cardiovascular Diseases, 50(4), 294–310.CrossRefPubMed Melikian, N., De Bruyne, B., Fearon, W. F., & MacCarthy, P. A. (2008). The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Progress in Cardiovascular Diseases, 50(4), 294–310.CrossRefPubMed
92.
Zurück zum Zitat Seddon, B., Cook, A., Gothard, L., Salmon, E., Latus, K., Underwood, S. R., & Yarnold, J. (2002). Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiotherapy and Oncology, 64(1), 53–63.CrossRefPubMed Seddon, B., Cook, A., Gothard, L., Salmon, E., Latus, K., Underwood, S. R., & Yarnold, J. (2002). Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiotherapy and Oncology, 64(1), 53–63.CrossRefPubMed
93.
Zurück zum Zitat Marinescu, M. A., Loffler, A. I., Ouellette, M., Smith, L., Kramer, C. M., & Bourque, J. M. (2015). Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC: Cardiovascular Imaging, 8(2), 210–220.PubMed Marinescu, M. A., Loffler, A. I., Ouellette, M., Smith, L., Kramer, C. M., & Bourque, J. M. (2015). Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC: Cardiovascular Imaging, 8(2), 210–220.PubMed
94.
Zurück zum Zitat Tschope, C., & Van Linthout, S. (2014). New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Current Heart Failure Reports, 11(4), 436–444.CrossRefPubMedPubMedCentral Tschope, C., & Van Linthout, S. (2014). New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Current Heart Failure Reports, 11(4), 436–444.CrossRefPubMedPubMedCentral
95.
Zurück zum Zitat Faccini, A., Kaski, J. C., & Camici, P. G. (2016). Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. European Heart Journal, 37(23), 1799–1806.CrossRefPubMed Faccini, A., Kaski, J. C., & Camici, P. G. (2016). Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. European Heart Journal, 37(23), 1799–1806.CrossRefPubMed
96.
Zurück zum Zitat Camici, P. G., & Crea, F. (2007). Coronary microvascular dysfunction. The New England Journal of Medicine, 356(8), 830–840.CrossRefPubMed Camici, P. G., & Crea, F. (2007). Coronary microvascular dysfunction. The New England Journal of Medicine, 356(8), 830–840.CrossRefPubMed
97.
Zurück zum Zitat Richardson, R. B. (2009). Ionizing radiation and aging: rejuvenating an old idea. Aging (Albany NY), 1(11), 887–902.CrossRef Richardson, R. B. (2009). Ionizing radiation and aging: rejuvenating an old idea. Aging (Albany NY), 1(11), 887–902.CrossRef
98.
Zurück zum Zitat Baverstock, K., & Karotki, A. V. (2011). Towards a unifying theory of late stochastic effects of ionizing radiation. Mutation Research, 718(1–2), 1–9.PubMed Baverstock, K., & Karotki, A. V. (2011). Towards a unifying theory of late stochastic effects of ionizing radiation. Mutation Research, 718(1–2), 1–9.PubMed
99.
Zurück zum Zitat Furth, J., Upton, A. C., Christenberry, K. W., Benedict, W. H., & Moshman, J. (1954). Some late effects in mice of ionizing radiation from an experimental nuclear detonation. Radiology., 63(4), 562–570.CrossRefPubMed Furth, J., Upton, A. C., Christenberry, K. W., Benedict, W. H., & Moshman, J. (1954). Some late effects in mice of ionizing radiation from an experimental nuclear detonation. Radiology., 63(4), 562–570.CrossRefPubMed
100.
Zurück zum Zitat Sokolova, N. V., & Gorshenina, T. I. (1959). Relation of the localization of radiation injury to functional state of the organ. 1. Biulleten’ Eksperimental’, 48, 29–34. Sokolova, N. V., & Gorshenina, T. I. (1959). Relation of the localization of radiation injury to functional state of the organ. 1. Biulleten’ Eksperimental’, 48, 29–34.
101.
Zurück zum Zitat Edwards, A. A., & Lloyd, D. C. (1998). Risks from ionising radiation: deterministic effects. Journal of Radiological Protection, 18(3), 175–183.CrossRefPubMed Edwards, A. A., & Lloyd, D. C. (1998). Risks from ionising radiation: deterministic effects. Journal of Radiological Protection, 18(3), 175–183.CrossRefPubMed
102.
Zurück zum Zitat Huang, Y. J., Harrison, A., Sarkar, V., Rassiah-Szegedi, P., Zhao, H., Szegedi, M., Huang, L., Wilson, B., Gaffney, D. K., & Salter, B. J. (2016). Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging. Adv Radiat Oncol., 1(2), 106–114.CrossRefPubMedPubMedCentral Huang, Y. J., Harrison, A., Sarkar, V., Rassiah-Szegedi, P., Zhao, H., Szegedi, M., Huang, L., Wilson, B., Gaffney, D. K., & Salter, B. J. (2016). Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging. Adv Radiat Oncol., 1(2), 106–114.CrossRefPubMedPubMedCentral
103.
Zurück zum Zitat Rubin, E., Camara, J., Grayzel, D. M., & Zak, F. G. (1963). Radiation-induced cardiac fibrosis. The American Journal of Medicine, 34, 71–75.CrossRefPubMed Rubin, E., Camara, J., Grayzel, D. M., & Zak, F. G. (1963). Radiation-induced cardiac fibrosis. The American Journal of Medicine, 34, 71–75.CrossRefPubMed
104.
Zurück zum Zitat Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clinic Proceedings, 89(9), 1287–1306.CrossRefPubMed Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clinic Proceedings, 89(9), 1287–1306.CrossRefPubMed
105.
Zurück zum Zitat Cuomo, J. R., Sharma, G. K., Conger, P. D., & Weintraub, N. L. (2016). Novel concepts in radiation-induced cardiovascular disease. World Journal of Cardiology, 8(9), 504–519.CrossRefPubMedPubMedCentral Cuomo, J. R., Sharma, G. K., Conger, P. D., & Weintraub, N. L. (2016). Novel concepts in radiation-induced cardiovascular disease. World Journal of Cardiology, 8(9), 504–519.CrossRefPubMedPubMedCentral
106.
Zurück zum Zitat Antonadou, D., Coliarakis, N., Synodinou, M., Athanassiou, H., Kouveli, A., Verigos, C., et al. (2001). Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. International Journal of Radiation Oncology, Biology, Physics, 51(4), 915–922.CrossRefPubMed Antonadou, D., Coliarakis, N., Synodinou, M., Athanassiou, H., Kouveli, A., Verigos, C., et al. (2001). Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. International Journal of Radiation Oncology, Biology, Physics, 51(4), 915–922.CrossRefPubMed
107.
Zurück zum Zitat Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., Mizuno, K., Ohashi, Y., & MEGA Study Group. (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet., 368(9542), 1155–1163.CrossRefPubMed Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., Mizuno, K., Ohashi, Y., & MEGA Study Group. (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet., 368(9542), 1155–1163.CrossRefPubMed
108.
Zurück zum Zitat Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathe, D., et al. (2007). Pravastatin inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clinical Cancer Research, 13(18 Pt 1), 5331–5340.CrossRefPubMed Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathe, D., et al. (2007). Pravastatin inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clinical Cancer Research, 13(18 Pt 1), 5331–5340.CrossRefPubMed
109.
Zurück zum Zitat Holler, V., Buard, V., Gaugler, M. H., Guipaud, O., Baudelin, C., Sache, A., Perez Mdel, R., Squiban, C., Tamarat, R., Milliat, F., & Benderitter, M. (2009). Pravastatin limits radiation-induced vascular dysfunction in the skin. The Journal of Investigative Dermatology, 129(5), 1280–1291.CrossRefPubMed Holler, V., Buard, V., Gaugler, M. H., Guipaud, O., Baudelin, C., Sache, A., Perez Mdel, R., Squiban, C., Tamarat, R., Milliat, F., & Benderitter, M. (2009). Pravastatin limits radiation-induced vascular dysfunction in the skin. The Journal of Investigative Dermatology, 129(5), 1280–1291.CrossRefPubMed
110.
Zurück zum Zitat Dainiak, N., & Tan, B. J. (1995). Utility of biological membranes as indicators for radiation exposure: alterations in membrane structure and function over time. Stem Cells, 13(Suppl 1), 142–152.PubMed Dainiak, N., & Tan, B. J. (1995). Utility of biological membranes as indicators for radiation exposure: alterations in membrane structure and function over time. Stem Cells, 13(Suppl 1), 142–152.PubMed
111.
Zurück zum Zitat Lett, J. T. (1992). Damage to cellular DNA from particulate radiations, the efficacy of its processing and the radiosensitivity of mammalian cells. Emphasis on DNA double strand breaks and chromatin breaks. Radiation and Environmental Biophysics, 31(4), 257–277.CrossRefPubMed Lett, J. T. (1992). Damage to cellular DNA from particulate radiations, the efficacy of its processing and the radiosensitivity of mammalian cells. Emphasis on DNA double strand breaks and chromatin breaks. Radiation and Environmental Biophysics, 31(4), 257–277.CrossRefPubMed
112.
Zurück zum Zitat Amini P, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Cheki M, et al. Mechanisms for radioprotection by melatonin; can it be used as a radiation countermeasure? Curr Mol Pharmacol. 2018. Amini P, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Cheki M, et al. Mechanisms for radioprotection by melatonin; can it be used as a radiation countermeasure? Curr Mol Pharmacol. 2018.
113.
Zurück zum Zitat Pokharel, S., Rasoul, S., Roks, A. J., van Leeuwen, R. E., van Luyn, M. J., Deelman, L. E., Smits, J. F., Carretero, O., van Gilst, W., & Pinto, Y. M. (2002). N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension., 40(2), 155–161.CrossRefPubMed Pokharel, S., Rasoul, S., Roks, A. J., van Leeuwen, R. E., van Luyn, M. J., Deelman, L. E., Smits, J. F., Carretero, O., van Gilst, W., & Pinto, Y. M. (2002). N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension., 40(2), 155–161.CrossRefPubMed
114.
Zurück zum Zitat Sharma, U., Rhaleb, N. E., Pokharel, S., Harding, P., Rasoul, S., Peng, H., & Carretero, O. A. (2008). Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. American Journal of Physiology. Heart and Circulatory Physiology, 294(3), H1226–H1232.CrossRefPubMed Sharma, U., Rhaleb, N. E., Pokharel, S., Harding, P., Rasoul, S., Peng, H., & Carretero, O. A. (2008). Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. American Journal of Physiology. Heart and Circulatory Physiology, 294(3), H1226–H1232.CrossRefPubMed
115.
Zurück zum Zitat Rhaleb, N. E., Pokharel, S., Sharma, U., & Carretero, O. A. (2011). Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. Journal of Hypertension, 29(2), 330–338.CrossRefPubMedPubMedCentral Rhaleb, N. E., Pokharel, S., Sharma, U., & Carretero, O. A. (2011). Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. Journal of Hypertension, 29(2), 330–338.CrossRefPubMedPubMedCentral
116.
Zurück zum Zitat Rhaleb, N. E., Pokharel, S., Sharma, U. C., Peng, H., Peterson, E., Harding, P., Yang, X. P., & Carretero, O. A. (2013). N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1beta-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflügers Archiv, 465(10), 1487–1495.CrossRefPubMed Rhaleb, N. E., Pokharel, S., Sharma, U. C., Peng, H., Peterson, E., Harding, P., Yang, X. P., & Carretero, O. A. (2013). N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1beta-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflügers Archiv, 465(10), 1487–1495.CrossRefPubMed
117.
Zurück zum Zitat Liu, Y. H., D'Ambrosio, M., Liao, T. D., Peng, H., Rhaleb, N. E., Sharma, U., André, S., Gabius, H. J., & Carretero, O. A. (2009). N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. American Journal of Physiology. Heart and Circulatory Physiology, 296(2), H404–H412.CrossRefPubMed Liu, Y. H., D'Ambrosio, M., Liao, T. D., Peng, H., Rhaleb, N. E., Sharma, U., André, S., Gabius, H. J., & Carretero, O. A. (2009). N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. American Journal of Physiology. Heart and Circulatory Physiology, 296(2), H404–H412.CrossRefPubMed
118.
Zurück zum Zitat Grillon, C., Rieger, K., Bakala, J., Schott, D., Morgat, J. L., Hannappel, E., Voelter, W., & Lenfant, M. (1990). Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters, 274(1–2), 30–34.PubMed Grillon, C., Rieger, K., Bakala, J., Schott, D., Morgat, J. L., Hannappel, E., Voelter, W., & Lenfant, M. (1990). Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters, 274(1–2), 30–34.PubMed
119.
Zurück zum Zitat Lenfant, M., Grillon, C., Rieger, K. J., Sotty, D., & Wdzieczak-Bakala, J. (1991). Formation of acetyl-Ser-Asp-Lys-Pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4. Annals of the New York Academy of Sciences, 628, 115–125.CrossRefPubMed Lenfant, M., Grillon, C., Rieger, K. J., Sotty, D., & Wdzieczak-Bakala, J. (1991). Formation of acetyl-Ser-Asp-Lys-Pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4. Annals of the New York Academy of Sciences, 628, 115–125.CrossRefPubMed
120.
Zurück zum Zitat Lipshultz, S. E., Sanders, S. P., Goorin, A. M., Krischer, J. P., Sallan, S. E., & Colan, S. D. (1994). Monitoring for anthracycline cardiotoxicity. Pediatrics., 93(3), 433–437.PubMed Lipshultz, S. E., Sanders, S. P., Goorin, A. M., Krischer, J. P., Sallan, S. E., & Colan, S. D. (1994). Monitoring for anthracycline cardiotoxicity. Pediatrics., 93(3), 433–437.PubMed
121.
Zurück zum Zitat Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., Oeffinger, K. C., Rosenthal, D. N., Sable, C. A., Sallan, S. E., Singh, G. K., Steinberger, J., Cochran, T. R., Wilkinson, J. D., & American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiolo. (2013). Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation., 128(17), 1927–1995.CrossRefPubMed Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., Oeffinger, K. C., Rosenthal, D. N., Sable, C. A., Sallan, S. E., Singh, G. K., Steinberger, J., Cochran, T. R., Wilkinson, J. D., & American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiolo. (2013). Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation., 128(17), 1927–1995.CrossRefPubMed
122.
Zurück zum Zitat Shankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., et al. (2008). Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics., 121(2), e387–ee96.CrossRefPubMed Shankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., et al. (2008). Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics., 121(2), e387–ee96.CrossRefPubMed
123.
Zurück zum Zitat Fulbright, J. M. (2011). Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice, 2011. Fulbright, J. M. (2011). Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiology Research and Practice, 2011.
124.
Zurück zum Zitat van Dalen, E. C., van den Brug, M., Caron, H. N., & Kremer, L. C. (2006). Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. European Journal of Cancer, 42(18), 3199–3205.CrossRefPubMed van Dalen, E. C., van den Brug, M., Caron, H. N., & Kremer, L. C. (2006). Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. European Journal of Cancer, 42(18), 3199–3205.CrossRefPubMed
125.
Zurück zum Zitat Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine, 351(2), 145–153.CrossRefPubMed Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine, 351(2), 145–153.CrossRefPubMed
126.
Zurück zum Zitat Malik, A., Jeyaraj, P. A., Calton, R., Uppal, B., Negi, P., Shankar, A., Patil, J., & Mahajan, M. K. (2016). Are biomarkers predictive of anthracycline-induced cardiac dysfunction? Asian Pacific Journal of Cancer Prevention, 17(4), 2301–2305.CrossRefPubMed Malik, A., Jeyaraj, P. A., Calton, R., Uppal, B., Negi, P., Shankar, A., Patil, J., & Mahajan, M. K. (2016). Are biomarkers predictive of anthracycline-induced cardiac dysfunction? Asian Pacific Journal of Cancer Prevention, 17(4), 2301–2305.CrossRefPubMed
127.
Zurück zum Zitat Landier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., Freeman, C. R., Friedman, D. L., Green, D. M., Marina, N., Meadows, A. T., Neglia, J. P., Oeffinger, K. C., Robison, L. L., Ruccione, K. S., Sklar, C. A., & Hudson, M. M. (2004). Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. Journal of Clinical Oncology, 22(24), 4979–4990.CrossRefPubMed Landier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., Freeman, C. R., Friedman, D. L., Green, D. M., Marina, N., Meadows, A. T., Neglia, J. P., Oeffinger, K. C., Robison, L. L., Ruccione, K. S., Sklar, C. A., & Hudson, M. M. (2004). Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. Journal of Clinical Oncology, 22(24), 4979–4990.CrossRefPubMed
128.
Zurück zum Zitat Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of Clinical Oncology, 30(10), 1042–1049.CrossRefPubMedPubMedCentral Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of Clinical Oncology, 30(10), 1042–1049.CrossRefPubMedPubMedCentral
129.
Zurück zum Zitat Zhang, C. J., Pei, X. L., Song, F. Y., Guo, Y., Zhang, Q. L., Shu, X. H., et al. (2017). Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT., 34(11), 1593–1600. Zhang, C. J., Pei, X. L., Song, F. Y., Guo, Y., Zhang, Q. L., Shu, X. H., et al. (2017). Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT., 34(11), 1593–1600.
130.
Zurück zum Zitat Lipshultz, S. E., Landy, D. C., Lopez-Mitnik, G., Lipsitz, S. R., Hinkle, A. S., Constine, L. S., et al. (2012). Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Journal of Clinical Oncology, 30(10), 1050–1057.CrossRefPubMedPubMedCentral Lipshultz, S. E., Landy, D. C., Lopez-Mitnik, G., Lipsitz, S. R., Hinkle, A. S., Constine, L. S., et al. (2012). Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Journal of Clinical Oncology, 30(10), 1050–1057.CrossRefPubMedPubMedCentral
131.
Zurück zum Zitat Leger, K. J., Leonard, D., Nielson, D., de Lemos, J. A., Mammen, P. P., & Winick, N. J. (2017). Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. Journal of the American Heart Association, 6(4), e004653.CrossRefPubMedPubMedCentral Leger, K. J., Leonard, D., Nielson, D., de Lemos, J. A., Mammen, P. P., & Winick, N. J. (2017). Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. Journal of the American Heart Association, 6(4), e004653.CrossRefPubMedPubMedCentral
132.
Zurück zum Zitat Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 23(Suppl 7:vii), 155–166.CrossRef Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 23(Suppl 7:vii), 155–166.CrossRef
133.
Zurück zum Zitat Akam-Venkata, J., Franco, V. I., & Lipshultz, S. E. (2016). Late cardiotoxicity: issues for childhood cancer survivors. Current Treatment Options in Cardiovascular Medicine, 18(7), 47.CrossRefPubMed Akam-Venkata, J., Franco, V. I., & Lipshultz, S. E. (2016). Late cardiotoxicity: issues for childhood cancer survivors. Current Treatment Options in Cardiovascular Medicine, 18(7), 47.CrossRefPubMed
134.
Zurück zum Zitat Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr., D. E., Colvin, M. M., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation., 136(6), e137–ee61.CrossRefPubMed Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr., D. E., Colvin, M. M., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation., 136(6), e137–ee61.CrossRefPubMed
135.
Zurück zum Zitat Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre 2nd, V. C., Shaikh, S. L., Mone, S. M., et al. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology, 20(23), 4517–4522.CrossRefPubMed Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre 2nd, V. C., Shaikh, S. L., Mone, S. M., et al. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology, 20(23), 4517–4522.CrossRefPubMed
136.
Zurück zum Zitat Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., Kimball, T. R., Delaat, C., Steinherz, L. J., & Zhao, H. (2004). Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology, 22(5), 820–828.CrossRefPubMed Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., Kimball, T. R., Delaat, C., Steinherz, L. J., & Zhao, H. (2004). Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology, 22(5), 820–828.CrossRefPubMed
137.
Zurück zum Zitat El-Shitany, N. A., Tolba, O. A., El-Shanshory, M. R., & El-Hawary, E. E. (2012). Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. Journal of Cardiac Failure, 18(8), 607–613.CrossRefPubMed El-Shitany, N. A., Tolba, O. A., El-Shanshory, M. R., & El-Hawary, E. E. (2012). Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. Journal of Cardiac Failure, 18(8), 607–613.CrossRefPubMed
138.
Zurück zum Zitat Shakir, D. K., & Rasul, K. I. (2009). Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. Journal of Clinical Medical Research, 1(1), 8–12. Shakir, D. K., & Rasul, K. I. (2009). Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. Journal of Clinical Medical Research, 1(1), 8–12.
139.
Zurück zum Zitat Lipshultz, S. E., & Colan, S. D. (2004). Cardiovascular trials in long-term survivors of childhood cancer. Journal of Clinical Oncology, 22(5), 769–773.CrossRefPubMed Lipshultz, S. E., & Colan, S. D. (2004). Cardiovascular trials in long-term survivors of childhood cancer. Journal of Clinical Oncology, 22(5), 769–773.CrossRefPubMed
140.
Zurück zum Zitat Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine, 354(23), 2443–2451.CrossRefPubMed Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine, 354(23), 2443–2451.CrossRefPubMed
141.
Zurück zum Zitat Hallas, J., Christensen, R., Andersen, M., Friis, S., & Bjerrum, L. (2012). Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. British Journal of Clinical Pharmacology, 74(1), 180–188.CrossRefPubMedPubMedCentral Hallas, J., Christensen, R., Andersen, M., Friis, S., & Bjerrum, L. (2012). Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. British Journal of Clinical Pharmacology, 74(1), 180–188.CrossRefPubMedPubMedCentral
142.
Zurück zum Zitat Ward, K. M., Binns, H., Chin, C., Webber, S. A., Canter, C. E., & Pahl, E. (2004). Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. The Journal of Heart and Lung Transplantation, 23(9), 1040–1045.CrossRefPubMed Ward, K. M., Binns, H., Chin, C., Webber, S. A., Canter, C. E., & Pahl, E. (2004). Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. The Journal of Heart and Lung Transplantation, 23(9), 1040–1045.CrossRefPubMed
143.
Zurück zum Zitat Bock, M. J., Pahl, E., Rusconi, P. G., Boyle, G. J., Parent, J. J., Twist, C. J., et al. (2017). Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: a report from the Pediatric Heart Transplant Study (PHTS) group. Pediatr Transplant, 21(5). Bock, M. J., Pahl, E., Rusconi, P. G., Boyle, G. J., Parent, J. J., Twist, C. J., et al. (2017). Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: a report from the Pediatric Heart Transplant Study (PHTS) group. Pediatr Transplant, 21(5).
144.
Zurück zum Zitat Cox, C. L., Hudson, M. M., Mertens, A., Oeffinger, K., Whitton, J., Montgomery, M., & Robison, L. L. (2009). Medical screening participation in the childhood cancer survivor study. Archives of Internal Medicine, 169(5), 454–462.CrossRefPubMedPubMedCentral Cox, C. L., Hudson, M. M., Mertens, A., Oeffinger, K., Whitton, J., Montgomery, M., & Robison, L. L. (2009). Medical screening participation in the childhood cancer survivor study. Archives of Internal Medicine, 169(5), 454–462.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cardiovascular diseases in survivors of childhood cancer
verfasst von
Neha Bansal
Javier G. Blanco
Umesh C. Sharma
Saraswati Pokharel
Shannon Shisler
Steven E. Lipshultz
Publikationsdatum
06.02.2020
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2020
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09859-w

Weitere Artikel der Ausgabe 1/2020

Cancer and Metastasis Reviews 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.